|
Real-time Estimate
Cboe BZX
11:49:29 2026-09-14 EDT
|
5-day change | 1st Jan Change | ||
| 24.78 USD | +1.54% |
|
-2.17% | +61.85% |
| 09-01 | Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating | MT |
| 08-06 | Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.81B | - | - | - | ||
| 66.93B | |||||
| 61.97B | |||||
| 28.26B | - | ||||
| 24.59B | |||||
| 24.3B | - |
- Stock Market
- Stocks
- XNCR Stock
- Charts Xencor, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
